Descripción de la empresa
Evolus, Inc. operates as a performance beauty company that delivers cash-pay aesthetic products across the United States, Canada, Europe, and Australia, with a specific focus on offering Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation designed for the temporary improvement in the appearance of moderate wrinkles. The firm functions within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, a classification that signifies its role in producing specialized pharmaceutical compounds rather than mass-market consumer goods. As of the latest reporting period, the company maintains a market capitalization of $265.44M and employs a workforce of 334 individuals to support its international distribution and manufacturing operations. These valuation and revenue figures indicate that Evolus, Inc. holds a mid-cap position in its niche, reflecting a business that has achieved significant scale in the aesthetic medicine market while retaining the operational characteristics of a specialized generic drug manufacturer.
Salud financiera
The company reported a trailing twelve-month revenue of $297.18M, yet it recorded a net income loss of $51,641,000 and an EBITDA of $-30,094,000, revealing a substantial gap between top-line generation and bottom-line profitability that points to a cost structure dominated by high operating expenses or significant one-time charges. This negative free cash flow of $-26,697,750 suggests that the company is currently burning cash, which limits its immediate financial flexibility to fund internal expansion without relying on external capital markets. The margin profile further illustrates these financial pressures, with a gross margin of 66.3% indicating strong pricing power or low cost of goods sold, contrasted sharply by an operating margin of -0.3% and a profit margin of -17.4% that highlight the heavy burden of overhead costs on the bottom line. On the balance sheet, the firm holds $53.83M in cash against total debt of $155.00M, a configuration that necessitates careful monitoring of liquidity, though the debt-to-equity ratio is listed as N/A due to the lack of positive equity. The current ratio stands at 1.90, a metric that indicates the company possesses sufficient current assets to cover its short-term liabilities nearly twice over, providing a buffer against immediate liquidity crises. Additionally, the Return on Equity is N/A and the Return on Assets is -10.3%, metrics that collectively reveal that management effectiveness in generating returns on shareholder capital and total assets is currently negative, a common trait for growth-stage biotech or specialty pharmaceutical firms.
Evaluación de valoración
Valuation multiples for Evolus, Inc. present a complex picture, with a trailing P/E ratio listed as N/A due to the net loss, while the forward P/E is projected at 17.00, implying that the market expects a significant turnaround in earnings trajectory to justify future earnings per share. The price-to-book ratio is recorded at -11.49, a negative figure that indicates the market is pricing the stock well below its book value, often seen in companies with intangible assets like intellectual property that are not fully captured on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.89 and an EV/EBITDA of -12.18, suggesting that investors are valuing the company primarily on its revenue generation capabilities rather than current profitability or earnings power. Regarding price action, the 52-week high was $12.28 and the low was $3.86, placing the current market price within a volatile trading range that reflects the uncertainty surrounding the company's path to profitability. The stock exhibits a Beta of 1.00, meaning its price volatility moves in tandem with the broader market, lacking the defensive characteristics of healthcare stocks or the aggressive leverage often found in distressed biotech firms.
Growth & Income
Revenue growth stands at 14.4% year-over-year, demonstrating a robust expansion in top-line sales, whereas earnings growth is N/A due to the absence of net income, indicating that top-line expansion has not yet translated into bottom-line profitability. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows a capital allocation strategy where earnings are theoretically reinvested into growth initiatives rather than distributed to shareholders. The absence of a dividend payout ratio is consistent with the company's current financial state, where cash reserves are likely being prioritized for R&D, regulatory approvals, or market expansion to achieve sustainable profitability. Overall, the growth and income profile of Evolus, Inc. is characterized by double-digit revenue expansion coupled with negative earnings, a dynamic typical of specialty drug manufacturers investing heavily in growth before reaching the maturity stage where they can support shareholder returns.